Novartis seeks to expand Leqvio into heart disease prevention

No­var­tis an­nounced Wednes­day that Leqvio low­ered bad cho­les­terol lev­els, com­pared with a place­bo or the cho­les­terol-low­er­ing drug eze­tim­ibe, in pa­tients at low-to-mod­er­ate risk of de­vel­op­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.